Conditions

This post was originally published on this site The investigational therapy ATYR1923 for pulmonary sarcoidosis may help decrease lung inflammation by halting the infiltration of immune cells called neutrophils into the lungs, according to a preclinical study in mice. Suzanne Paz, PhD, from the therapy’s developer aTyr Pharma, presented the findings in a poster, titled “ATYR1923…

This post was originally published on this site An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new formulation also led to similar levels of daratumumab in circulation, meeting the trial’s co-primary goals, according to Genmab, the…

This post was originally published on this site Mirvetuximab soravtansine, an investigational antibody-drug conjugate targeting the folate receptor alpha (FRα) protein, was no better than chemotherapy at delaying disease progression or death in ovarian cancer patients included in the FORWARD I Phase 3 trial. The treatment failed to extend survival without disease worsening in the…

This post was originally published on this site Aiming to support the development of CMD-502, a new cell-based therapy that uses donor-derived natural killer T-cells to fight cancer, the Cancer Prevention and Research Institute of Texas (CPRIT) has awarded Cell Medica an $8.7 million grant. In addition to being available “off-the-shelf,” the therapy — being developed in collaboration with the Baylor…

This post was originally published on this site With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,”…

This post was originally published on this site Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), sponsored by Janssen, is testing 300 mg daily Zejula in patients whose disease worsened after treatment with…

This post was originally published on this site Since 1989, between 384,000 and 615,000 women’s lives have been spared thanks to significant advancements in breast cancer screening methods and treatment, a study reports. The findings of the study, “Breast cancer deaths averted over 3 decades,” were published in Cancer. Statistics from the National Cancer Institute’s…

This post was originally published on this site The presence of specific subtypes of immune cells in the tumor environment of people with follicular lymphoma can predict how a patient’s immune system will respond to the disease, as well as survival outcomes, a study shows. The study, “Mass Cytometry Analysis Reveals that Specific Intratumoral CD4+ T…

This post was originally published on this site Immune checkpoint inhibitors may be safe and effective in advanced cancer patients with human immunodeficiency virus (HIV), according to a review study. The research, “Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review,” was published in JAMA Oncology. HIV-positive patients have a…

This post was originally published on this site Gamida Cell’s natural killer cell treatment is a promising approach to treat adults with relapsed or refractory non-Hodgkin’s lymphoma or multiple myeloma, according to early data from an ongoing Phase 1 clinical trial. Data from the first 14 patients showed that the treatment was well-tolerated and eliminated cancer signs in…

This post was originally published on this site A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel (NCT03732820), the trial was recently presented at the 2019 Genitourinary Cancers Symposium, in San Francisco, in a poster…